Janssen Pharmaceuticals, Inc. has obtained worldwide rights, excluding China and Korea, to develop and commercialize oxyntomodulin-based therapies from Hanmi Pharmaceutical Co. The agreement includes HM12525A, a biologic expected to enter Phase II studies next year.   HM12525A is an oxyntomodulin-based therapy (GLP-1/glucagon receptor dual agonist) that has been shown to improve multiple metabolic parameters that lead to improved blood glucose, body weight, and insulin sensitivity, as a once w...